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RAR-related orphan receptor  (ROR) is a nuclear receptor
that plays an essential role in the development of T helper 17
(Th17) cells of the adaptive immune system. TheNLRP3 inflam-
masome is a component of the innate immune system that pro-
cesses interleukin (IL)-1 into a mature cytokine. Elevated
activity of theNLRP3 inflammasomecontributes to the progres-
sion of an array of inflammatory diseases. Bone marrow–
derived macrophages (BMDMs) isolated from ROR-null mice
displayed reduced capacity to secrete IL-1, and they also dis-
played a reduction inNlrp3 and Il1b gene expression. Examina-
tion of the promoters of the Il1b andNlrp3 genes revealed mul-
tiple putative ROR response elements (ROREs) that were
occupied by ROR. ROR inverse agonists were effective inhib-
itors of the inflammasome. ROR inverse agonists suppressed
lipopolysaccharide (LPS)/ATP-stimulated IL-1 secretion and
expression of Il1b andNlrp3 in BMDMs. Additionally, the abil-
ity of the ROR inverse agonists to suppress IL-1 secretionwas
lost in Nlrp3-null macrophages. The potential for targeting the
NLRP3 inflammasome in vivo using ROR inverse agonists was
examined in two models: LPS-induced sepsis and fulminant
hepatitis. Pharmacological inhibition of ROR activity reduced
plasma IL-1 as well as IL-1 production by peritoneal macro-
phages in a model of LPS-induced sepsis. Additionally, ROR
inverse agonists reduced mortality in an LPS/D-galactosamine–
induced fulminant hepatitis mouse model. These results illus-
trate amajor role for ROR in regulation of innate immunity via
modulation of NLRP3 inflammasome activity. Furthermore,
these data suggest that inhibiting the NLRP3 inflammasome
with ROR inverse agonists may be an effective method to treat
NLRP3-associated diseases.
The NLRP3 inflammasome complex is a critical component
of the innate immune system and functions as a central sensor
of pathogen-associated and/or cellular damage–associated
molecules. Upon activation by these pathogen/damage-associ-
ated molecules, the NLRP3 inflammasome facilitates pro-
cessing and secretion of the pro-inflammatory cytokine IL-13
(1). Activation of theNLRP3 inflammasome requires two steps.
First, the expression of genes encoding proteins critical for
NLRP3 inflammasome function, such as Nlrp3 and Il1b, is
induced by “priming” with a pro-inflammatory stimuli, such as
lipopolysaccharide (LPS). Then damage- or pathogen-associ-
ated molecular patterns (DAMPs or PAMPs) act as secondary
signals to trigger several pathways activating the assembly of
the NLRP3 inflammasome and activation of caspase-1–depen-
dent processing of proIL-1 to mature IL-1. A wide range of
DAMPs/PAMPs that activate the NLRP3 inflammasome have
been identified, including cholesterol and urate crystals, reac-
tive oxygen species, ATP,-amyloid, and bacterial toxins (2–4).
Thus, the function of the inflammasome is tightly regulated by
multiple signals that limit unconstrained production of IL-1.
Inappropriate regulation of NLRP3 inflammasome activity
is associated with significant pathology. Abnormally elevated
NLRP3 inflammasome activity is fundamental in the develop-
ment of IL-1–driven diseases, including atherosclerosis,
Alzheimer’s disease, and rheumatoid arthritis, where accumu-
lation of crystals of cholesterol, -amyloid, or hydroxyapatite
is perceived as an endogenous sterile stress (2, 5, 6). Thus, phar-
macological suppression of the NLRP3 inflammasome may
be a reasonable target for development of a new class of thera-
peutics to treat a number of diseases associated with elevated
inflammation.
Nuclear receptors are a large family of ligand-dependent
transcription factors involved in regulation of developmental,
metabolic, and inflammatory processes. The retinoic acid
receptor–related orphan receptors (RORs) are a subgroup of
nuclear receptors that are well-known as regulators of the cir-
cadian rhythm, metabolism, and immune function (7–9). The
ROR subfamily is composed of three members: ROR, ROR,
and ROR. ROR has been the focus of particularly intense
investigation due to its role as a critical factor driving T-helper
17 (Th17) lymphocyte differentiation and function (10). Regu-
lation of Th17 cell differentiation and function is particularly
important with regard to autoimmune diseases, where the
number and activity of these cells are elevated. We and others
have demonstrated that targeting inhibition of ROR activity
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with inverse agonists is an effective method for suppressing
Th17 cell differentiation and function as well as treatment of
autoimmune diseases in rodent models (7, 11–13). Several of
these ROR inverse agonists are now being evaluated in clinical
trials to treat autoimmune diseases such as psoriasis (14).
Beyond Th17 lymphocytes, ROR is also expressed in innate
immune cells, such asmacrophages and natural killer cells, sug-
gesting a wider role for ROR beyond Th17 cell differentiation
and function in regulation of immunity.
In this report, we describe the regulation of the NLRP3
inflammasome by ROR via direct regulation ofNlrp3 and Il1b
gene expression. Furthermore, we demonstrate that ROR in-
verse agonists effectively inhibit NLRP3 inflammasome activity
in vitro and in vivo, suggesting that this class of drug may have
much wider utility in the treatment of inflammatory disorders
than originally anticipated.
Results
ROR is required for normal NLRP3 inflammasome activity in
macrophages
We recently demonstrated that the nuclear receptor
REV-ERB plays a role in regulation of the NLRP3 inflam-
masome (15). Bone marrow–derived macrophages (BMDMs)
from Rev-erb-null mice display elevated Nlpr3 and Il1b gene
expression due to the inability of REV-ERB to suppress the
expression of these genes (15). Given that ROR often func-
tions in a reciprocal manner to REV-ERB, we performed a sim-
ilar experiment in BMDMs from ROR-null mice. BMDMs
were cultured for 6 days and then polarized (M1) or not (M0)
with LPS (100 ng/ml) for 24 h.After treatment,M0 andM1cells
were treatedwith LPS (100 ng/ml) for 1 h to activate theNLRP3
inflammasome. As illustrated in Fig. 1B,Nlrp3 and Il1b expres-
sion was significantly reduced inM1 BMDMs from ROR-null
mice relative to WT M1 BMDM under LPS-stimulated condi-
tions. In undifferentiatedM0 BMDMs, we observed thatNlrp3
gene expression was reduced following LPS treatment in the
ROR-null cells, but Il1b expression was not changed (Fig.
1A). We then assessed the effect of ROR deletion on IL-1
secretion. BMDMs were polarized for 24 h with LPS (100
ng/ml) followed by treatment with ATP for varying lengths
of time (1, 15, or 120 min) to simulate IL-1 secretion. We
observed an attenuation in Il-1 secretion from the ROR
knockout (KO) BMDMs compared with WT cells at the 1-
and 15-min times post-ATP stimulation (Fig. 1C). Although
we observed25% decrease in Nlrp3 gene expression in M1
polarized BMDMs (Fig. 1B), NLRP3 protein expression was
only suppressed 8% in the ROR-null BMDMs (M1 polar-
ized) (Fig. 1D). Even with the relatively small reduction in
NLRP3 expression, intracellular IL-1 protein expression
(proIL-1 and cleaved IL-1) was substantially reduced in
ROR KO macrophages compared with WT macrophages
(Fig. 1D). These data indicate that ROR plays a role in the
regulation of NLRP3 inflammasome activity. Loss of ROR
results in reduced responsiveness of the NLRP3 inflam-
masome, and our data suggest that ROR is necessary for
normal expression of Nlrp3 and Il1b expression.
ROR inverse agonists SR2211 and SR1555 suppress Nlrp3
and Il1b gene expression
ROR appears to be required for the response of the NLRP3
inflammasome to inflammatory stimuli, such as LPS/ATP. In
light of this finding, we then examined the effect of ROR-
specific inverse agonists SR2211 and/or SR1555 (16, 17) on
Nlrp3 and Il1b gene expression. BMDMs from WT animals
differentiated for 7 days in culture and then treated for 24hwith
LPS (100 ng/ml). Macrophages were then treated with DMSO,
SR2211 (10 M), LPS (100 ng/ml), or LPS plus SR2211 for 24 h
prior to assessment of gene expression. Treatment with ROR
inverse agonist SR2211 decreased the expression of bothNlrp3
and Il-1 genes, in the presence or absence of LPS (Fig. 2A). The
same results were observed with SR1555, another ROR selec-
tive inverse agonist (Fig. 2B). The effects of the ROR inverse
agonist were selective to Nlrp3 and Il1b, as the expression
of other inflammasome components (caspase-1, Asc, Aim2,
Nlrp1a, Nlrp1b, Nlrc4, caspase-11) was unaffected by SR2211
treatment (Fig. 2C).
Given the clear effects of pharmacological inhibition of
ROR, we also assessed the effects of SR2211 and SR1555 on
IL-1 secretion from BMDMs. Treatment with either ROR
inverse agonist induced a decrease of IL-1 secretion by the
macrophages after 2 h of ATP stimulation (Fig. 2,D and E). We
then studied the protein level of IL-1 and caspase-1 activity in
response to SR2211 in macrophages.
To determine whether the effects of the ROR inverse ago-
nists on IL-1 secretion were dependent on targeting NLRP3
inflammasome activity, we tested the effect of a ROR inverse
agonist inNlrp3-null BMDMs.The basal level of IL-1 secreted
by these macrophages was low compared with WT macro-
phages, and most importantly, the ROR inverse agonist
SR1555 had no effect on IL-1 secretion in the Nlrp3-null
macrophages, indicating that the effect of the ROR targeted
drug depended on the NLRP3 inflammasome (Fig. 2F).We also
tested the specificity of SR1555 in ROR KO BMDMs. Cells
were treated with DMSO or SR1555 in the presence or absence
of LPS. As expected, we did not see any effect of SR1555 on
Nlrp3, Il1b gene expression, or IL-1 production (Fig. S1).
Next, we sought to determine whether the effects we observed
in themouse are conserved in humans.We examined the effect
of SR1555 in primary human macrophages in vitro in the pres-
ence of LPS. Treatment with SR1555 decreased NLRP3 and
IL1B gene expression in human cells, suggesting that ROR
regulates this pathway in humans as well as mice (Fig. S2).
These data clearly suggest that targeting ROR with pharma-
cological agents may be an effective method to inhibit NLRP3
inflammasome activity.
ROR response elements are located in the promoters of the
Nlrp3 and Il1b genes
Based on our data indicating that ROR is required for nor-
mal expression of Nlrp3 and Il1b as well as our recent study
describing the direct regulation of these genes by REV-ERB, a
nuclear receptor that typically recognizes similar or identical
response elements as ROR (18), we sought to determine
whether ROR directly binds to response elements in the pro-
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moters of the Nlrp3 and Il1b genes. Two functional REV-ERB
response elements were identified in the promoter of the Il1b
gene and four were identified in the promoter of theNlrp3 gene
(15), and we focused on determining whether these were also
bound by ROR using ChIP (Fig. 3A). RAW267.4 macrophages
were used and ChIP was performed using an antibody directed
against ROR, and the putative ROREs were analyzed by RT-
qPCR.We observed enrichment of ROR at all four sites within
theNlrp3 promoter, with the1.2-kb site providing the great-
est signal (Fig. 3A), and both sites within the Il1b promoter also
displayed enriched ROR binding (Fig. 3B). As a negative con-
trol, we assessed the potential binding of ROR at a site 4 kb
upstream of the transcription start site of the Il1b gene with no
identifiable RORE. We observed no signal at this site (Fig. 3B).
To further confirm direct binding of ROR to these putative
ROREs, we performed electrophoretic mobility shift assays. As
shown in Fig. 3C, in vitro transcribed/translated ROR protein
induced a mobility shift of a radiolabeled RORE derived from
Figure 1. NLRP3 inflammasome activity is reduced in BMDMs from ROR-null mice. A, Nlrp3 (left) and Il1b (right) gene expression in M1 BMDMs derived
fromWT and ROR KO mice in response to no treatment or LPS treatment. B, Nlrp3 (left) and Il1b (right) gene expression in M0 BMDMs derived fromWT and
ROR KOmice in response to no treatment or LPS treatment. C, IL-1 secreted fromM1 BDMDs fromWT or ROR KOmice treated with LPS after 0, 15, or 120
min of ATP stimulation. D, NLRP3 and IL-1 protein expression fromWT or ROR KOM1 polarized BMDMs (18-h treatment with 100 ng/ml LPS) followed by a
medium change with (LPS) or without (NT) an additional 24-h LPS treatment. The bottom panel provides normalization of the level of expression of NLRP3,
proIL-1, and cleaved IL-1 to actin expression. *, p 0.05; **, p 0.01; ***, p 0.001 by Student’s t test. Error bars, S.E.
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theBmal1 promoter (left panel, left lane). If a 10molar excess
of amutated Bmal1 ROREwas added as a competitor, therewas
no effect on ROR binding to the labeled RORE (middle lane).
However, if unlabeledWT Bmal1 ROREwas used as a compet-
itor, the binding of ROR to the labeled ROREwas significantly
reduced. We performed identical analysis using the two puta-
Figure 2. ROR inverse agonist reduce NLRP3 inflammasome activity. A, Nlrp3 (left) and Il1b (right) gene expression in M1 BMDMs (LPS or no treatment)
treated with vehicle or ROR inverse agonist SR2211 (10 M). B, Nlrp3 (left) and Il1b (right) gene expression in M1 BMDMs (LPS or no treatment) treated with
vehicle or ROR inverse agonist SR1555 (10 M). C, expression of various inflammasome/inflammasome-associated genes in response to treatment with
SR1555. M1 BMDMswere treatedwith LPS and SR1555 as in B.D, IL-1 secretion byM1 BMDMs treatedwith vehicle, LPS, or LPS SR2211 (10M) followed by
ATP treatment (0, 15, or 120 min) after LPS treatment. E, IL-1 secretion by M1 BMDMs treated with vehicle, LPS, or LPS SR1555 (10 M) followed by ATP
treatment (0, 15, or 120min) after LPS treatment. F, IL-1 production from BMDM Nlrp3 KO treated with LPS (50 ng/ml) and SR1555 (10M) in the presence of
ATP. *, p 0.05; **, p 0.01; ***, p 0.001 by Student’s t test. Error bars, S.E.
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Figure 3. Identification of RORbinding siteswithin theNlrp3 and Il1bpromoters by ChIP. A, a schematic of theNlrp3 promoter is shown in the top panel
with theputativeROREs. Thebottompanel shows the results of ChIP/QPCRat the fourputativeROREs, indicatingenrichmentof ROR at eachof these four sites.
B, a schematic of the Il1b promoter is shown in the top panel with the putative ROREs. The bottom panel shows the results of ChIP/QPCR at the two putative
ROREs, indicating enrichment of ROR at each of these. A negative control was also used 4 kb upstream of the Il1b TSS that did not contain a putative RORE. C,
EMSA demonstrating the ability of ROR (in vitro transcribed/translated) to bind to the radiolabeled ROREs from Il1b and Nlrp3 promoters. In the left panel, a
positive control (Bmal1 RORE) is used without an unlabeled competitor (left lane; no competitor), a 10molar excess of unlabeled mutant competitor RORE
(middle lane; cold mutant competitor), and a 10molar excess of competitor (right lane; cold WT RORE). In the four right-hand panels of C, the two proximal
RORE elements from the Nlrp3 promoter and the two ROREs within the Il1b promoter were examined in a similar manner as the Bmal1 RORE EMSA. Arrows,
RORE–ROR complexes. Error bars, S.E.
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tive ROREs derived from the proximal Nlrp3 promoter as well
the two ROREs from the Il1b promoter and observed similar
results. These data indicate that, like REV-ERB, ROR recog-
nizes specific DNA sequences in the promoters of the Nlrp3
and Il1b genes, allowing direct regulation of expression of these
genes.
ROR inverse agonists inhibit NLRP3 inflammasome activity in
amousemodel of sepsis
Given the effect of ROR inverse agonists on suppression
of NLRP3 inflammasome activity, we sought to determine
whether these pharmacological agents may be effective inhibi-
tors of the inflammasome in vivo. We initially utilized an acute
model of sterile peritoneal inflammation that mimics many
aspects of the inflammatory response in sepsis (15). Mice were
pretreated with SR2211 or vehicle and challenged by intraperi-
toneal administration of LPS to specifically activate the NLRP3
signaling pathway (19). Animals were sacrificed 6 or 12 h after
LPS challenge, and blood and peritoneal macrophages were
collected. After 2 h in culture, supernatant from the macro-
phages was collected and analyzed with an IL-1 ELISA. As
shown in Fig. 4A, plasma IL-1 levels were significantly
reduced in SR2211-treated mice 6 h after LPS administration.
The IL-1 levels were reduced at 12 h after LPS administration
versus 6 h, at which time the SR2211 did not have an effect on
IL-1 levels. IL-1 secretion from the isolated peritoneal
macrophages was also suppressed by SR2211 treatment 6 h
after LPS administration. Similar to the plasma data, IL-1
secretion was reduced at 12 h versus 6 h after LPS administra-
tion, and at this time, the SR2211 had lost its effect (Fig. 4B).
Thus, in alignment with the in vitro macrophages data, these
results suggest that pharmacological suppression of ROR
leads to suppression of IL-1 secretion consistent with inhibi-
tion of NLRP3 inflammasome activity.
ROR inverse agonists reducemortality due to fulminant
hepatitis
Acute liver failure, also known as fulminant hepatitis (FH), is
a conditionwhere rapid deterioration of liver function results in
coagulopathy and can be fatal within hours. Excessive activa-
tion of immune cells, mainly liver macrophages, is involved in
the development of the disease, leading to hepatocyte necrosis,
systemic inflammation, and liver failure (20). Despite advances
in treatment, FH carries a very high mortality, especially in
young adults. The treatments for FH are very limited, and liver
transplant remains one of the major treatments. Low doses of
LPS in combination with the specific hepatotoxic agent D-ga-
lactosamine (GalN) promotes specific liver injury and recapit-
ulates the clinical picture of acute liver injury in humans (21).
LPS activates Toll-like receptors and their downstream signal-
ing pathway, leading to the expression of pro-inflammatory
cytokines, including Il-1, whose secretion is governed by acti-
vation of theNLRP3 inflammasome via the combination of LPS
andGaIN in the FHmodel. REV-ERB agonists are very effective
in reducing NLRP3 inflammasome activity and reducing mor-
tality in this mousemodel of FH (15). Because our data indicate
that ROR regulates the NLRP3 inflammasome in a similar
manner, we sought to determine whether ROR inverse ago-
nists also display efficacy in this model. We assessed the ability
of two selective ROR inverse agonists, SR1555 and SR2211, in
this model. Three-month-old WT animals were treated with
ROR inverse agonist SR1555, SR2211, or vehicle both 13 h and
1 h before LPS-GaIN injection. Both ROR inverse agonists
displayed similar efficacy, more than doubling the survival rate
of mice in the FH model (Fig. 4C). Because the ROR inverse
agonists were quite effective reducing mortality in this model,
we decided to repeat the experiment but collected tissue 6 h
after inducing the acute liver injury. As illustrated in Fig. 4D, the
LPS/GalN treatment significantly altered liver morphology rel-
ative to nontreated (N.T.) control livers. The diseased livers
were black and necrotic, whereas livers frommice treated with
either SR2211 or SR1555 displayed much more normal color-
ation (Fig. 4C). Histologically, H&E-stained liver sections dis-
play considerable damage in the LPS/GalN-treated mice versus
the nontreated mice (Fig. 4D). SR2211 and SR1555 treatment
clearly had a protective effect against LPS/GaIN–induced liver
damage as observed in the sections, but there were still signs of
hepatocellular toxicity, albeit considerably reduced relative to
vehicle-treated livers. Expression of Nlrp3 and Il1b was signif-
icantly reduced in the livers from mice treated with either
SR1555 or SR2211 relative to the vehicle-treated mice. These
data clearly indicate that ROR inverse agonists are protective
in the mouse model of FH and suggest that at least one clear
mechanism underlying this protection is inhibition of NLRP3
inflammasome activity.
Discussion
Excessive NLRP3 inflammasome activity is responsible for
chronic inflammation that drives pathological processes in
multiple diseases, including atherosclerosis, Alzheimer’s dis-
ease, fulminant hepatitis, and diabetes (2, 3, 20, 22). In fact,
many of these disease processes are significantly attenuated in
mice that lack NLRP3 inflammasome functionality (22–24).
Thus, the NLRP3 inflammasome has emerged as a valid phar-
macological target for the treatment of a range of diseases. The
NLRP3 inflammasome is activated in response to PAMPs/
DAMPs, and this activation up-regulates pro-inflammatory
cytokine production, including IL-1. Activation of the NLRP3
inflammasome requires a two-step mechanism as follows. 1)
“Priming” induces the transcription of the key inflammasome/
cytokine genes (such as LPS). 2) A distinct signal is required for
inflammasome assembly and activation. A variety of secondary
signals that drive NLRP3 inflammasome assembly and activity
have now been described and include cholesterol crystals, ATP,
or reactive oxygen species. Hence, theNLRP3 inflammasome is
a key platform coordinating the inflammatory response after
integration of information from various stimuli.
In this study, we found that ROR binds to the promoters of
the Nlrp3 and Il1b genes and drives the expression of these
genes. Although a previous study showed that a ROR inverse
agonist inhibited Il-1 secretion from RAW264.7 cells, the
mechanism of such an effect was not investigated (25). We
observed that loss of ROR leads to reduced Nlrp3 and Il1b
expression in macrophages. Selective ROR inverse agonists
also suppress Nlrp3 and Il1b expression and reduce NLRP3
inflammasome activity, as evidenced by reduced IL-1 secre-
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tion both in cultured macrophages and in vivo. Suppression of
IL-1 secretion by RORwas clearly mediated by targeting the
NLRP3 inflammasome because the effect of a ROR inverse
agonist was lost in macrophages derived fromNlrp3-null mice.
We also demonstrated that pharmacological targeting of
ROR is an effective method for reducing acute inflammation
in disease models associated with excessive activation of the
NLRP3 inflammasome, including sepsis (sterile) and FH. In FH,
there is rapid and massive necrosis of the liver due to severe
acute inflammation leading to coma and cerebral edema over a
period of several days to several weeks. Symptoms of FH
become severe very rapidly, and in many cases, the only effec-
Figure 4. ROR inverse agonist are effective in treatment of sepsis and fulminant hepatitis via targeting the NLRP3 inflammasome. A, plasma IL-1
level in mice treated with vehicle or SR2211 at 6 or 12 h after LPS administration (n 6/group). B, IL-1 level secreted by peritoneal macrophages in culture
collected from mice treated with vehicle or SR2211 at 6 or 12 h after LPS injection. C, Kaplan–Meier survival curve of mice in a fulminant hepatitis model
challengedwith LPS/GalN andpretreated or notwith vehicle (black line, n 10), SR2211 (gray line, n 10/group), or SR1555 (red line, n 10).D, representative
appearance of livers fromuntreated (not LPS/GalN), vehicle-treated, SR2211-treated, and SR1555-treated animals 6 h after LPSGaIN injection.WT liver from
anontreated animal is used as a healthy liver reference. E, representativeH&E-stained liver fromuntreated (no LPS/GalN), vehicle-treated, SR2211-treated, and
SR1555-treated animals 6 h after LPSGaIN injection. WT liver from a nontreated animal (N.T.) is used as a healthy liver reference. F, RT-qPCR analysis ofNlrp3
and Il1bgene expression fromvehicle-, SR2211-, and SR1555-treated animals 6 h after LPSGaIN injection. *, p 0.05; **, p 0.01; ***, p 0.001 by Student’s
t test. Error bars, S.E.
ACCELERATED COMMUNICATION: ROR regulates the NLRP3 inflammasome














tive treatment is liver transplant. Excessive NLRP3 inflam-
masome activity has been linked to the pathological effects of
FH, and acetaminophen overdose, a leading cause of FH, has
been associatedwith extremeNLRP3 inflammasome activation
(26, 27). Although it is possible that additional ROR-depen-
dentmechanismmay be important for the efficacy in treatment
of FH, it is very likely that inhibiting the NLRP3 inflammasome
is one important component.
Clearly, targeting inhibition of the NLRP3 inflammasome
holds potential for treatment of FH as well as a range of other
diseases associated with abnormal NLRP3 inflammasome
activity, and ROR inverse agonists appear to be effectively
inhibiting its activity. Unlike other recently described NLRP3
inflammasome inhibitors that directly target the assembly of
the NLRP3 inflammasome (such as MCC950) (27), ROR tar-
gets the expression of a critical component of the inflam-
masome (theNlrp3 gene) as well as the substrate for the inflam-
masome (the Il1b gene), providing a distinct mechanism for
suppression of activity. Based on their distinct mechanisms of
action, it may be possible to derive additional efficacy in target-
ing inflammation by using both of these classes of drugs.
We recently found that the nuclear receptor REV-ERB
regulates the NLRP3 inflammasome. Given that RORs and
REV-ERBs recognize similar or, in many cases, identical
DNA response elements, we were able to determine that
these receptors are recognizing the same elements within
the Nlrp3 and Il1b promoters (15). REV-ERB is a repressor
of transcription, whereas ROR is an activator of transcrip-
tion. The REV-ERB agonists that drive active repression of
gene transcription appear to be much more efficacious in
reducing NLRP3 activity than the ROR inverse agonists.
The greater level of efficacy of REV-ERB agonists is also
conserved in the FH model, where the REV-ERB agonist,
SR9009, was able to protect against mortality to a much
greater extent than the ROR inverse agonists. We believe
this is likely because the ROR inverse agonists can only
block the activator action of ROR occupying the promoters,
whereas the REV-ERB agonist is effective in recruiting core-
pressors to the promoters, driving inhibition of any level of
activation of transcription of the promoter. Thus, the REV-
ERB agonists should be quite effective in blocking any acti-
vation of Nlrp3 or Il1b transcription from any source.
A number of ROR inverse agonists are under clinical devel-
opment based on the ability of ROR to suppress Th17 cell
development and function (14). Our group, as well as the Litt-
man group (13), were the first to identify ROR inverse agonists
and characterize their ability to suppress Th17 cell develop-
ment/function and reduce the severity of autoimmune disease
in rodent models (7). However, with the current study, we now
understand that ROR plays a much wider role in immune
function, where it targets a critical component of the innate
immune system, the NLRP3 inflammasome.With the progres-
sion of ROR inverse agonists in clinical development, there
should be examination of their potential to be used in situations




8–12-week-oldC57BL/6 or RORKOmicewere euthanized
according to the animal protocols approved by Saint Louis Uni-
versity institutional animal care and use committee. Bonemar-
row hematopoietic stem cells were isolated from the tibia and
femur and cultured during 1 week in Dulbecco’s modified
Eagle’s medium, 20% L929-conditioned medium containing
macrophage colony–stimulating factor and 10% fetal bovine
serum. BMDMs were either pretreated with the ROR inverse
agonist and treated with LPS (100 ng/ml) or cultured with LPS
and treated with ROR inverse agonist (10 M) or vehicle. For
the ELISA,macrophages were primed with LPS (100 ng/ml) for
12 h and activated for 30 min to 2 h with ATP pH 7 (5 mmol/
liter). The supernatants were collected, cleared by centrifuga-
tion, and analyzed by ELISA using the mouse Il-1 (R&D) kit
according to the manufacturer’s instructions.
Human primarymacrophages
Cells were obtained fromStemCell Technologies and treated
with LPS (100 ng/ml) in the presence of SR1555 (5 M) or
DMSO for 24 h.
Quantitative real-time PCR
Total RNA was isolated from mouse tissues using PureLink
RNAmini kit (Ambion). RNAwas reverse-transcribed to make
cDNA using the qScriptTM cDNA synthesis kit (Quanta Biosci-
ences) according to the manufacturer’s instructions. Real-time
PCR was performed using a SYBR Green PCR master mix kit
(Roche Applied Science). Primers were purchased from Inte-
grated DNA Technologies.
Western blotting
Twenty-five g of protein in Laemmli buffer were separated
using SDS-PAGE and transferred to polyvinylidene difluoride
membranes. After saturation in 10% skimmed milk, mem-
branes were incubated with the primary antibody directed
against IL-1 (1:1000; REF), NLRP3 (1:1000; AG-20B-0014,
Adipogen), or actin (1:1000; sc-1616, Santa Cruz Biotechnol-
ogy, Inc.) in Tris-buffered saline–bovine serum albumin solu-
tion (2.5%). Then appropriate horseradish peroxidase–coupled
secondary antibody diluted (1:10,000) in 10% skimmed milk
(1.15363.0500, Merck Millipore) was used.
ChIP
ChIP experiments were performed in RAW264.7 cells using
Simple ChIP Plus Sonication ChIP Kit (catalog no. 57976, Cell
Signaling) according to the manufacturer’s instructions.
Electrophoretic mobility shift assay (EMSA)
Murine ROR proteinwas obtained by in vitro transcription/
translation (TNT kit, Promega). The different single-stranded
oligonucleotides (forward) were [32P]ATP-labeled with T4
polynucleotide kinase (Promega) before annealing with their
unlabeled antisense (reverse) oligonucleotide partners. Probes
were purified and counted, and 20,000 cpm were used for each
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binding reaction. Unlabeled specific and nonspecific competi-
tor probes were included at the indicated molar excess.
Animals and treatment
All procedures were approved and conducted in accordance
with the Saint Louis University institutional animal care and
use committee.
Fulminant hepatitis
10-week-old WT male mice were intraperitoneally injected
with LPS (Sigma-Aldrich) and D-galactosamine hydrochloride.
For SR2211 and SR1555 treatment, mice were pretreated with
SR2211 or SR1555 or vehicle (10% DMSO, 10% Tween PBS).
After 16 h, mice received another intraperitoneal injection of
SR2211 or SR1555 or vehicle followed by intraperitoneal injec-
tion of LPS and D-galactosamine hydrochloride. To determine
the survival rate, mice were monitored every 60 min after LPS/
D-GalN injection for 48 h. In another experiment, mice were
sacrificed 6 h after LPS/D-GalN administration, and blood and
liver were harvested. Histology and gene expression were per-
formed on liver.
Peritonitis
For peritonitis experiments, 10-week-old WT male mice
were intraperitoneally injected with the SR2211 at ZT23 and
with LPS 1 h after SR2211 injection at ZT0. Mice were sacri-
ficed every 4 h after LPS injection and peritoneal lavage was
performedwith sterile PBS. PECswere cultured, and cell super-
natants were collected after 2 h. IL-1 protein content was then
quantified by ELISA.
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